The stock price performance over the year has been a mixed bag, resulting in a range of outlooks from optimistic to pessimistic depending on the observer. This year’s metric has recorded a Price increase of 79.51%. However, over the past six months, we’ve seen a weaker performance of 27.45%. The price of XGN fallen by 16.27% over the last 30 days. And in the last five days, it has surged by 1.38%.
The stock market performance of Exagen Inc has been very steady. Over the last year, the company’s stock hit its highest at $7.82 on 06/18/25, while the lowest price during the same time frame was $1.71, recorded on 07/05/24.
52-week price history of XGN Stock
The history of a stock’s 52-week high and low prices can provide important information about its current state and future potential. Exagen Inc’s current trading price is -5.94% away from its 52-week high, while its distance from the 52-week low is 330.41%. The stock’s price range for this period has been between $1.71 and $7.82. The Healthcare sector company’s shares saw a trading volume of about 0.29 million for the day, which was higher than the average daily volume of 0.22 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
Exagen Inc (XGN) has experienced a quarterly rise of 96.27% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 160.85M and boasts a workforce of 209 employees.
How Moving Averages and Trading Volume Data Work Together
XGN’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for XGN stands at 3.66. Similarly, the long-term debt-to-equity ratio is also 3.09.
